As We See It: Age-Reversal Update

William Faloon

Readers of this magazine learn about healthy choices they can make today to reduce disease risk and slow premature aging.

We also fund research that aims to reverse biological aging.

It was not until 2015 that the scientific community began to recognize that current techniques may enable partial age reversal to occur.

Our goal in studying emerging rejuvenation treatments is to validate what works, what fails, and what potencies are needed to provide real-world benefits.

An example is senolytics, where the purpose is to remove senescent cells that otherwise inflict massive tissue damage.^1,2

The importance of this research is such that it is being funded by a grant from the National Institutes of Health.^3-5

We are assisting a major university in identifying blood markers to enable precise dosing of senolytic compounds like quercetin and fisetin.

Even the federal government recognizes that if validated senolytic treatments become widely available, Medicare can be spared astronomical medical financial outlays.

I receive invitations to speak at conferences and have been given honorariums as high as $30,000. These groups are eager to learn what they might do to reverse degenerative changes in their aged bodies.

I donate all honorariums to charitable organizations that are engaged in research that has no profit motive.

This means that discoveries can be made available to humanity without delays caused by patent applications and intellectual property disputes.

As a reader of this magazine, you don’t pay anything for the information described in the article "The Prospect of Human Age Reversal" which contains highlights from a conference at which I presented.

Your support via supplement purchases and blood tests enables us to fund these rejuvenation research initiatives.

For those seeking to delay aging today, the article "What’s in Mushrooms That Supports Healthy Aging?" reveals fascinating data on how eating a particular food group can add healthy years to your life expectancy.

For longer life,

William Faloon

References

1. Hickson LJ, Langhi Prata LGP, Bobart SA, et al. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine. 2019 Sep;47:446-56.
2. Justice JN, Nambiar AM, Tchkonia T, et al. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicinee. 2019 Feb;40:554-63.
3. Available at: https://now.tufts.edu/articles/taking-harmful-cells-contribute-disease. Accessed December 20, 2021.
4. Available at: https://www.buckinstitute.org/news/the-first-non-invasive-biomarker-to-track-and-verify-efficacy-of-senolytic-drugs/. Accessed December 20, 2021.
5. Available at: https://www.buckinstitute.org/news/8303/. Accessed December 20, 2021.